Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

Overview of attention for article published in JACC, April 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 7 news outlets
policy: 1 policy source
twitter: 214 X users

patent: 6 patents
facebook: 1 Facebook page

Citations

dimensions_citation: 422 Dimensions

Readers on

mendeley: 304 Mendeley

Summary News Policy documents X Patents Facebook Dimensions citations

So far, Altmetric has seen 280 X posts from 214 X users, with an upper bound of 765,372 followers.

@kaulcsmc @gcfmd @JavedButler1 @texhern @DCRINews Therapy for myocardial infarction, both PCIand medical, has improved so much that it is very difficult to show the efficacy of any intervention We demonstrated that SGLT2i improve remodeling in postMI pigs

20 Mar 2024

Reply Repost Favourite

RT @ApoThera: Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular…

21 Jan 2023

Reply Repost Favourite

RT @ApoThera: Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular…

21 Jan 2023

Reply Repost Favourite

RT @ApoThera: Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular…

21 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 276 additional X posts.